-$0.46 EPS Expected for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) This Quarter

Share on StockTwits

Equities analysts forecast that ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) will post ($0.46) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for ACADIA Pharmaceuticals’ earnings, with estimates ranging from ($0.60) to ($0.40). ACADIA Pharmaceuticals posted earnings of ($0.51) per share during the same quarter last year, which suggests a positive year over year growth rate of 9.8%. The business is scheduled to issue its next quarterly earnings report on Wednesday, August 14th.

On average, analysts expect that ACADIA Pharmaceuticals will report full year earnings of ($1.90) per share for the current fiscal year, with EPS estimates ranging from ($1.96) to ($1.83). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.12) per share, with EPS estimates ranging from ($1.94) to ($0.04). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.05). The firm had revenue of $62.90 million during the quarter, compared to analyst estimates of $60.93 million. ACADIA Pharmaceuticals had a negative net margin of 116.10% and a negative return on equity of 79.74%. The firm’s quarterly revenue was up 28.6% on a year-over-year basis. During the same period last year, the business posted ($0.44) earnings per share.

Several research firms have recently commented on ACAD. JPMorgan Chase & Co. reissued a “buy” rating on shares of ACADIA Pharmaceuticals in a research note on Sunday, March 3rd. Canaccord Genuity lifted their target price on ACADIA Pharmaceuticals from $23.00 to $27.00 and gave the company an “in-line” rating in a research note on Wednesday, February 27th. ValuEngine raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 14th. BidaskClub cut ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, February 22nd. Finally, Zacks Investment Research cut ACADIA Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 30th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. ACADIA Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $31.25.

Several large investors have recently bought and sold shares of the company. Teachers Advisors LLC lifted its stake in ACADIA Pharmaceuticals by 3.0% during the 3rd quarter. Teachers Advisors LLC now owns 250,406 shares of the biopharmaceutical company’s stock valued at $5,198,000 after acquiring an additional 7,358 shares during the period. Bank of Montreal Can lifted its stake in ACADIA Pharmaceuticals by 1,002.4% during the 4th quarter. Bank of Montreal Can now owns 13,603 shares of the biopharmaceutical company’s stock valued at $220,000 after acquiring an additional 12,369 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in ACADIA Pharmaceuticals by 39.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,935 shares of the biopharmaceutical company’s stock valued at $128,000 after acquiring an additional 2,242 shares during the period. Oppenheimer Asset Management Inc. acquired a new stake in ACADIA Pharmaceuticals during the 4th quarter valued at approximately $96,000. Finally, Xact Kapitalforvaltning AB lifted its stake in ACADIA Pharmaceuticals by 24.3% during the 4th quarter. Xact Kapitalforvaltning AB now owns 19,932 shares of the biopharmaceutical company’s stock valued at $322,000 after acquiring an additional 3,900 shares during the period. Institutional investors and hedge funds own 93.35% of the company’s stock.

Shares of NASDAQ ACAD traded down $1.37 during midday trading on Friday, hitting $24.26. The stock had a trading volume of 947,958 shares, compared to its average volume of 807,405. The stock has a market capitalization of $3.50 billion, a P/E ratio of -12.51 and a beta of 2.95. ACADIA Pharmaceuticals has a fifty-two week low of $12.77 and a fifty-two week high of $28.67. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.29 and a current ratio of 6.35.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

See Also: What is a Buy-Side Analyst?

Get a free copy of the Zacks research report on ACADIA Pharmaceuticals (ACAD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MKM Partners Lowers ADTRAN  Price Target to $17.00
MKM Partners Lowers ADTRAN Price Target to $17.00
Apple  PT Raised to $180.00 at Nomura
Apple PT Raised to $180.00 at Nomura
Advaxis  Lowered to “Hold” at ValuEngine
Advaxis Lowered to “Hold” at ValuEngine
Zacks Investment Research Upgrades Atlas Air Worldwide  to “Hold”
Zacks Investment Research Upgrades Atlas Air Worldwide to “Hold”
Apple  Raised to “Outperform” at Raymond James
Apple Raised to “Outperform” at Raymond James
Zacks Investment Research Lowers Agilysys  to Hold
Zacks Investment Research Lowers Agilysys to Hold


© 2006-2019 Ticker Report